A prospective, single-arm, multicentre, exploratory clinical study of the efficacy and safety of dasatinib combined with prednisone in oral treatment of Ph+ Acute Lymphoblastic Leukemia

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000038053

Enrollment

Unknown

Registered

2020-09-09

Start date

2020-09-14

Completion date

Unknown

Last updated

2020-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphoblastic leukemia

Interventions

dasatinib combined with prednisone group:dasatinib combined with prednisone

Eligibility

Sex/Gender

All

Age

16 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Patients with Ph+ acute lymphoblastic leukemia initially diagnosed. The diagnostic criteria refer to 2016 WHO typing. 2) Aged >= 16 years. 3) The ECOG score of the Eastern Oncology Cooperative group was 0~3. 4) life expectancy > for 8 weeks. 5) one can provide informed consent, can understand and comply with the requirements of the study.

Exclusion criteria

Exclusion criteria: Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
Complete remission (CR);	—

Secondary

Measure	Time frame
Hematological and non-hematological adverse reactions;minimal residual disease (MRD);MMR;hospital stays;overall survival (OS);Disease-free survival (DFS);	—

Countries

China

Contacts

Public ContactHong-Hu Zhu

The First Affiliated Hospital of Zhejiang University School of Medicine

zhuhhdoc@163.com+86 13671232272

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026